Plain-English translation of NCT07224373 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing AZD0120, a new type of treatment that uses your own immune cells to fight multiple sclerosis. Researchers have designed these cells to target and reduce the cells in your body that are causing your MS. The study will check whether this medication is safe and what dose works best for people whose MS hasn't gotten better with standard treatments.
Some people with multiple sclerosis continue to have symptoms and disease progression even while taking strong medicines. This trial exists to see if this medication—a newer approach using engineered immune cells—might help patients whose condition hasn't improved with current treatments.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will undergo screening tests to confirm you qualify. The study will then collect some of your blood cells, process them in a laboratory to create the treatment, and return them to your body (likely as an infusion). You will be monitored closely with follow-up visits to check for side effects and how well the treatment is working. The exact schedule and duration will depend on which disease group you join and how your body responds.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States